Recruiting
Phase 3
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
Condition(s) studied
Metastatic Non-Small Cell Lung CancerNSCLC Stage IVOligoProgressive Metastatic Disease
Investigational drug(s) / intervention(s)
Stereotactic Body Radiotherapysecond-line systemic therapy
Stereotactic Body Radiotherapy: The dose of radiation therapy is determined by the radiologist based on the clinical parameters of the lesion, including tumor size and location. In most cases, radiotherapy fractionation regimens range from 27-30 Gy/3 Fractions or 30-50 Gy/5 Fractions, and appropriate radiotherapy doses covering 27-70 Gy/3-10 Fractions can also be selected by the radiologist based on radiation limitations of neighboring endangered organs.
second-line systemic therapy: a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen
Study summary
The goal of this clinical trial is to learn if Stereotactic Body Radiotherapy (SBRT) can treat the oligo-progressive metastatic non-small cell lung cancer (NSCLC) after first-line chemotherapy. The main questions it aims to answer are:
Does SBRT improve progression-free survival in oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy? Does SBRT improve overall survival and quality of life in oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy?
Researchers will compare SBRT in combination with standard of care (SOC) and SOC only to see if SBRT works to treat oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy.
Participants will:
Take SBRT in combination with SOC or SOC only. Visit the clinic for checkups and tests as required by the study. Keep a diary of their symptoms and complete the quality of life assessment questionnaire.
Eligibility
Inclusion Criteria:
* Age ≥ 18 years. Gender is not limited.
* Histologically and/or cytologically confirmed stage IV metastatic NSCLC.
* Eastern Cooperative Oncology Group (ECOG) score of 0-2.
* Patients who had prior first-line chemotherapy with clinical benefit lasting for ≥3 months.
* Driver gene-negative NSCLC patients with oligo-progression during first-line chemotherapy combined with Immune Checkpoint Inhibitors (ICI). Driver gene-positive NSCLC patients, such as epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) fusion positivity, are allowed to enroll if oligo-progression occurred during treatment with first-line chemotherapy combined with bevacizumab ± ICI after failure of Tyrosine Kinase Inhibitor (TKI) therapy.
* Progressive sites were assessed as ≤5 according to RECIST v1.1 criteria combined with positron emission tomography / computertomography (PET/CT), and all were located extracranially. Progressive lymph node lesions are counted by region, with each lymph node region amenable to concurrent SBRT (which may contain multiple progressive lymph nodes) counted as 1 progressive site.
* All progressive sites should be visible on radiologic imaging and assessed as suitable for SBRT treatment by a radiotherapist.
* Intracranial progressive lesions and symptomatic lesions can be treated with palliative radiotherapy and local therapy prior to enrollment and are not counted within the oligo-progressive sites.
* Expected survival time greater than 3 months.
* Comprehensive examination completed within 28 days prior to enrollment in the study and a complete blood count/differential, collected within 15 days, showing that the patient has normal internal organ function and normal bone marrow function.
* Negative serum or urine pregnancy test in females of childbearing age within 14 days prior to study enrollment.
* Patients are willing to provide written informed consent and must be willing to adhere to the prescribed follow-up schedule.
Exclusion Criteria:
* Currently participating in an interventional clinical study treatment that may affect this study, or have been treated with another investigational drug or investigational device that may affect this study within 4 weeks prior to first treatment.
* Pregnant or lactating women.
* Progression sites deemed unsuitable for SBRT treatment as assessed by radiotherapy specialists.
* Presence of untreated intracranial metastases or symptomatic progressive sites.
* History of malignancy other than NSCLC or untreated primary malignancy within the past 3 years.
* Serious active comorbidities that would interfere with treatment in this study.
* History or evidence of disease that could interfere with the results of the trial, prevent the subject from participating in the study throughout, abnormal values of treatment or laboratory tests, or other conditions that, in the opinion of the investigator, make enrollment inappropriate.
Primary outcome measure(s)
- progression-free survival (PFS) — Time from date of randomization until the date of first documented progression or date of death from any cause after the second-line treatment, whichever came first, assessed up to 18 months.
Progression-free survival, PFS: Time from date of randomization until the date of first documented progression or date of death from any cause after the second-line treatment, whichever came first.
Trial sites (1)
| Facility | City | Region | Status |
|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University |
Hangzhou |
Zhejiang |
Recruiting |
More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China
Other trials for the same condition
